Aller au contenu

Interactions médicamenteuses

Aprepitant + Encorafenib

Gravité: Majeure

Aprepitant and Encorafenib: major interaction.

Dernière mise à jour

Réservé aux professionnels de santé — à titre de référence uniquement. Cette page est un bref résumé, pas un avis médical, et ne remplace ni la notice officielle ni le jugement clinique. Vérifiez toujours avant de prescrire ou de délivrer.

Le contenu clinique de cette page n'est disponible qu'en anglais.

Résumé

Aprepitant can increase encorafenib concentrations through CYP3A4 inhibition. Higher exposure raises the risk of encorafenib toxicity including QT prolongation, dermatologic effects and hepatotoxicity.

Ce que signifie cette interaction, en termes simples

Aprepitant and Encorafenib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.

Aprepitant belongs to Gastrointestinal Tract; Encorafenib belongs to Oncology.

Niveau de preuve: Moderate

Pourquoi elle survient

Aprepitant inhibits CYP3A4, reducing the metabolism of encorafenib.

Conduite à tenir

Prefer an antiemetic without CYP3A4 inhibition. If unavoidable, reduce encorafenib to half the dose and monitor QTc, then resume the prior dose after the inhibitor is stopped for 3 to 5 half-lives.

Questions à poser à votre pharmacien

  • Does the benefit of taking both outweigh the risk in my case?
  • Do I need any blood test, ECG or other check while on both?
  • What early warning signs should I watch for, and what should I do if they appear?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Réservé aux membres Pro+

Débloquer la page complète

Créez un compte et lancez un essai Pro+ pour débloquer les conseils complets de prise en charge pour Aprepitant et Encorafenib, les notes complémentaires, le détail des données probantes et le vérificateur d'interactions pour une ordonnance complète.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Essayez Pro+ gratuitement pendant 14 jours sur le web. Sans carte.

Questions fréquentes

Can I take Aprepitant with Encorafenib?

MediHelp rates the interaction as major. Aprepitant and Encorafenib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Aprepitant can increase encorafenib concentrations through CYP3A4 inhibition. Higher exposure raises the risk of encorafenib toxicity including QT prolongation, dermatologic effects and hepatotoxicity.

How serious is the interaction between Aprepitant and Encorafenib?

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Prefer an antiemetic without CYP3A4 inhibition. If unavoidable, reduce encorafenib to half the dose and monitor QTc, then resume the prior dose after the inhibitor is stopped for 3 to 5 half-lives.

What other medicines interact with Aprepitant?

MediHelp also lists interactions of Aprepitant with, for example, Lomitapide, Pimozide, Avapritinib. The full list is on the Aprepitant page.

Monographies complètes, posologies et vérificateur d'interactions dans l'application MediHelp

Ouvrez le référentiel complet, vérifiez les interactions entre plusieurs médicaments et utilisez les outils de posologie dans l'application MediHelp.

Parcourir de A à Z · Interactions médicamenteuses

Télécharger l'app Se connecter